androgen deprivation therapy

October 2, 2019October 24, 2019

Erleada Cuts Risk of Death by 25% in Localized Castration-resistant Prostate Cancer, Phase 3 Trial Finds

News

Add-on treatment with Erleada (apalutamide) lowers the risk of death by 25% in men on androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of ... Read more

September 19, 2019

FDA Approves Erleada to Treat Metastatic Castration-sensitive Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer (mCSPC), or those whose cancer still responds to androgen deprivation ... Read more

August 5, 2019

Xtandi Delays Disease Worsening in Metastatic Hormone-sensitive Prostate Cancer, Study Says

News

Adding Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression or death in men with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of how spread the disease is, a Phase 3 ... Read more

July 29, 2019July 29, 2019

ADT Linked to Higher Alzheimer’s and Dementia Risk in Older Prostate Cancer Patients, Study Suggests

News

Men with prostate cancer who undergo treatment with androgen deprivation therapy (ADT) — a form of hormone therapy that aims to slow disease progression by reducing the levels of male ... Read more

May 22, 2019May 22, 2019

Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows

News

Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological imaging — or death in metastatic hormone-sensitive prostate cancer (mHSPC) patients, a Phase 3 clinical trial shows. ... Read more

April 24, 2019

Radiation, Hormone Therapy Extend Survival in Advanced PC, Phase 3 Trial Shows

News

A combination of androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) is better at delaying disease progression and extending survival of patients with locally advanced prostate cancer than ... Read more

February 4, 2019

Erleada Improves Survival in Metastatic Castration-Sensitive Prostate Cancer, Phase 3 Trial Finds

News

Adding Janssen‘s androgen receptor inhibitor Erleada (apalutamide) to first-line androgen deprivation therapy (ADT) significantly extended survival and delayed disease progression or death in metastatic castration-sensitive prostate cancer patients included in a Phase 3 ... Read more

January 2, 2019

ADT Increases Risk for Fractures in Older Prostate Cancer Patients, Study Shows

News

Elderly prostate cancer patients taking androgen deprivation therapy (ADT) have an increased risk for bone fractures compared to prostate cancer patients without ADT or men without prostate cancer, a study ... Read more

October 4, 2018

Surgery Plus Radiation Therapy Best at Extending Survival in Locally Advanced Prostate Cancer Patients, Study Says

News

A combination of surgery and radiation therapy is better at extending the survival of men with locally advanced prostate cancer than radiation therapy plus hormone therapy, but is associated with ... Read more